Omentin protects H9c2 cells against docetaxel cardiotoxicity

BACKGROUND: Association between obesity and cardiovascular diseases is well known, however increased susceptibility of obese patients to develop several cancer types is not so commonly known. Current data suggest that poorer overall survival in cancer patients might be associated to non-cancer-relat...

Descripción completa

Detalles Bibliográficos
Autores: Lage Fernández, Ricardo, Cebro Márquez, María, Rodríguez Mañero, Moises, González Juanatey, José Ramón, Moscoso Galán, Isabel
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/15487
Acceso en línea:https://www.ncbi.nlm.nih.gov/pubmed/30794687
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386316/pdf/pone.0212782.pdf
http://hdl.handle.net/20.500.11940/15487
Access Level:acceso abierto
Palabra clave:CHUS
IDIS
id ES_220ed66fa7cb8dd7bb397eb68d6c1bb5
oai_identifier_str oai:runa.sergas.gal:20.500.11940/15487
network_acronym_str ES
network_name_str España
repository_id_str
spelling Omentin protects H9c2 cells against docetaxel cardiotoxicityLage Fernández, RicardoCebro Márquez, MaríaRodríguez Mañero, MoisesGonzález Juanatey, José RamónMoscoso Galán, IsabelCHUSIDISBACKGROUND: Association between obesity and cardiovascular diseases is well known, however increased susceptibility of obese patients to develop several cancer types is not so commonly known. Current data suggest that poorer overall survival in cancer patients might be associated to non-cancer-related causes such as higher risk of cardiotoxicity in obese patients treated with chemotherapeutic agents. Omentin, a novel adipokine decreased in obesity, is actually in the spotlight due to its favourable effects on inflammation, glucose homeostasis and cardiovascular diseases. Also, recent data showed that in vitro anthracycline-induced cardiomyocyte apoptosis is counteracted by omentin suggesting its cardioprotective role. OBJECTIVE: Our aim was to evaluate omentin effects against docetaxel toxicity. RESULTS: Our data indicate that omentin inhibits docetaxel-induced viability loss and that increased viability is associated to decreased caspase-3 expression and cell death. Although omentin reduces NOX4 expression, it failed to reduce docetaxel-induced reactive oxygen species production. Our results indicate that omentin decreases docetaxel-induced endoplasmic reticulum stress, suggesting that cardioprotective role might be associated to ERS inhibition. CONCLUSION: These data suggest that omentin treatment may contribute to decrease susceptibility to DTX-induced cardiotoxicity.2019info:eu-repo/semantics/articlehttps://www.ncbi.nlm.nih.gov/pubmed/30794687https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386316/pdf/pone.0212782.pdfhttp://hdl.handle.net/20.500.11940/15487reponame:RUNA. Repositorio da Consellería de Sanidade e Sergasinstname:Servizo Galego de Saúde (SERGAS)Ingléshttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:runa.sergas.gal:20.500.11940/154872026-06-12T08:40:47Z
dc.title.none.fl_str_mv Omentin protects H9c2 cells against docetaxel cardiotoxicity
title Omentin protects H9c2 cells against docetaxel cardiotoxicity
spellingShingle Omentin protects H9c2 cells against docetaxel cardiotoxicity
Lage Fernández, Ricardo
CHUS
IDIS
title_short Omentin protects H9c2 cells against docetaxel cardiotoxicity
title_full Omentin protects H9c2 cells against docetaxel cardiotoxicity
title_fullStr Omentin protects H9c2 cells against docetaxel cardiotoxicity
title_full_unstemmed Omentin protects H9c2 cells against docetaxel cardiotoxicity
title_sort Omentin protects H9c2 cells against docetaxel cardiotoxicity
dc.creator.none.fl_str_mv Lage Fernández, Ricardo
Cebro Márquez, María
Rodríguez Mañero, Moises
González Juanatey, José Ramón
Moscoso Galán, Isabel
author Lage Fernández, Ricardo
author_facet Lage Fernández, Ricardo
Cebro Márquez, María
Rodríguez Mañero, Moises
González Juanatey, José Ramón
Moscoso Galán, Isabel
author_role author
author2 Cebro Márquez, María
Rodríguez Mañero, Moises
González Juanatey, José Ramón
Moscoso Galán, Isabel
author2_role author
author
author
author
dc.subject.none.fl_str_mv CHUS
IDIS
topic CHUS
IDIS
description BACKGROUND: Association between obesity and cardiovascular diseases is well known, however increased susceptibility of obese patients to develop several cancer types is not so commonly known. Current data suggest that poorer overall survival in cancer patients might be associated to non-cancer-related causes such as higher risk of cardiotoxicity in obese patients treated with chemotherapeutic agents. Omentin, a novel adipokine decreased in obesity, is actually in the spotlight due to its favourable effects on inflammation, glucose homeostasis and cardiovascular diseases. Also, recent data showed that in vitro anthracycline-induced cardiomyocyte apoptosis is counteracted by omentin suggesting its cardioprotective role. OBJECTIVE: Our aim was to evaluate omentin effects against docetaxel toxicity. RESULTS: Our data indicate that omentin inhibits docetaxel-induced viability loss and that increased viability is associated to decreased caspase-3 expression and cell death. Although omentin reduces NOX4 expression, it failed to reduce docetaxel-induced reactive oxygen species production. Our results indicate that omentin decreases docetaxel-induced endoplasmic reticulum stress, suggesting that cardioprotective role might be associated to ERS inhibition. CONCLUSION: These data suggest that omentin treatment may contribute to decrease susceptibility to DTX-induced cardiotoxicity.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://www.ncbi.nlm.nih.gov/pubmed/30794687
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386316/pdf/pone.0212782.pdf
http://hdl.handle.net/20.500.11940/15487
url https://www.ncbi.nlm.nih.gov/pubmed/30794687
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386316/pdf/pone.0212782.pdf
http://hdl.handle.net/20.500.11940/15487
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:RUNA. Repositorio da Consellería de Sanidade e Sergas
instname:Servizo Galego de Saúde (SERGAS)
instname_str Servizo Galego de Saúde (SERGAS)
reponame_str RUNA. Repositorio da Consellería de Sanidade e Sergas
collection RUNA. Repositorio da Consellería de Sanidade e Sergas
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404555087708160
score 15.300724

Similares en LA Referencia